Skip to Main Content

Women with certain types of ovarian and breast cancers are benefiting from a relatively new class of drugs known as PARP inhibitors. Soon, men with advanced prostate cancer might be helped, too.

Clovis Oncology (CLVS) disclosed new clinical trial results Friday showing a 44 percent tumor response rate following treatment with its PARP inhibitor, called Rubraca. The median duration of response has not yet been reached.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • I signed up and paid ..
    They won’t let me sign in and when I ask to reset password something sent to my e mail does not I need help..
    The reserve mail never gets to me..

Comments are closed.